Want to see AU:AT1 full AI Analyst Report?
AT1 Stock Chart & Stats
AU$0.04
>-AU$0.01(-5.00%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.05
Previous CloseN/A
Volume312.94K
Average Volume (3M)1.80M
Market Cap
AU$14.44M
Enterprise ValueAU$13.46M
Total Cash (Recent Filing)AU$3.51M
Total Debt (Recent Filing)AU$754.39K
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding902,432,860
10 Day Avg. Volume984,499
30 Day Avg. Volume1,797,539
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.30
Price to Sales (P/S)2.39
P/FCF Ratio-4.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$31.96M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal financial leverage (debt/equity ~0.03) gives Atomo durable financial flexibility versus highly leveraged peers. With low interest burden the company can prioritize product development, absorb near-term losses, and pursue partnerships or manufacturing scale without immediate refinancing pressure.
Proprietary RDT PlatformAtomo’s proprietary point-of-care and at-home RDT platform creates durable competitive advantages: platform licensing, customization services, and component supply build B2B stickiness. These capabilities support recurring OEM relationships and differentiated product roadmaps across disease indications.
Gross Margin LevelA near-50% gross margin indicates underlying manufacturing and product economics that can support sustainable unit profitability. If revenue growth resumes, existing gross margin provides room for operating leverage and incremental investment in R&D or commercialization without immediate margin compression.
Bears Say
Declining RevenueTwo-digit revenue decline signals structural demand or commercialization challenges for Atomo’s products. Persistent top-line contraction undermines scale benefits, slows payback on R&D and customer onboarding, and makes it harder to leverage fixed-cost manufacturing to restore profitability over the medium term.
Deep Operating LossesSeverely negative margins reflect ongoing failure to cover operating costs at current revenue levels. Sustained operating losses erode equity, necessitate external funding for operations, and constrain the company’s ability to scale commercialization or invest in strategic partnerships without dilutive financing.
Negative Cash Flow TrendOngoing negative operating and free cash flow, coupled with steep FCF deterioration, indicate weakening liquidity generation. This reduces capacity to self-fund working capital and capex, increases reliance on external capital, and elevates execution risk for commercial rollouts over the next several quarters.
Atomo Diagnostics Ltd. News
AT1 FAQ
What was Atomo Diagnostics Ltd.’s price range in the past 12 months?
Atomo Diagnostics Ltd. lowest share price was AU$0.02 and its highest was AU$0.05 in the past 12 months.
What is Atomo Diagnostics Ltd.’s market cap?
Atomo Diagnostics Ltd.’s market cap is AU$14.44M.
When is Atomo Diagnostics Ltd.’s upcoming earnings report date?
Atomo Diagnostics Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 40 days.
How were Atomo Diagnostics Ltd.’s earnings last quarter?
Currently, no data Available
Is Atomo Diagnostics Ltd. overvalued?
According to Wall Street analysts Atomo Diagnostics Ltd.’s price is currently Overvalued.
Does Atomo Diagnostics Ltd. pay dividends?
Atomo Diagnostics Ltd. does not currently pay dividends.
What is Atomo Diagnostics Ltd.’s EPS estimate?
Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atomo Diagnostics Ltd. have?
Atomo Diagnostics Ltd. has 902,432,860 shares outstanding.
What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:AT1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atomo Diagnostics Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.49%
Trailing 12-Months
Company Description
Atomo Diagnostics Ltd.
Established in 2010 and based in Leichhardt, Australia, Atomo Diagnostics Limited is a global enterprise focused on the innovation and commercialization of medical devices. The company provides swift-result diagnostic tools designed for various applications, including COVID-19 detection, HIV screening, pregnancy confirmation, and assessing respiratory conditions.
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―